Please assess the completion status of the following clinical trial:

Trial Title: Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria for Stages 1 and 2:~* HIV infected~* On a highly active antiretroviral regimen (HAART) including NVP and 2 nucleoside reverse transcriptase inhibitors and receiving a maintenance of NVP for at least 4 weeks prior to study entry and taking the current recommended oral dose every 12 hours~* Willing to swallow or chew study drugs~* Willing to be hospitalized for the 12 hour PK studies~* Willing to use acceptable forms of contraception~* Parent or guardian willing to provide informed consent~Inclusion Criteria for Stage 1:~* Between 12 to 30 kg (26.5 to 66.1 lbs)~Inclusion Criteria for Stage 2:~* Between 6 to 30 kg (13.2 to 66.1 lbs)~Exclusion Criteria:~* Certain abnormal laboratory values~* Require certain medications~* Grade 2 or greater vomiting within 30 days prior to study entry~* Grade 2 or greater diarrhea within 30 days prior to study entry~* History of immunological failure (CD4 percentage decrease of more than 30% within a 6-month period for children 6 years or younger OR CD4 cell count decrease of more than 30% within a 6-month period for children older than 6 years)~* Current treatment for acute serious bacterial, viral, or opportunistic infection~* History of dose-limiting toxicity requiring treatment discontinuation of any of the study drugs~* Known hypersensitivity to any of the study drugs~* Current surgical or medical problem affecting gastrointestinal motility or absorption (e.g., ileus, ulcerative colitis) or liver function~* Treatment with immune modulators or myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic drugs within 30 days prior to study entry. Patients who have received therapeutic vaccines are not excluded.~* Treatment with experimental drugs within 30 days of study entry~* Acute inflammation of the liver~* Chemotherapy for active cancer~* Any clinically significant diseases other than HIV infection or clinically significant findings that, in the investigator's opinion, may interfere with the study~* Inability to provide a reliable means of contact (e.g., telephone number)~* Pregnancy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- A, Stage 1 (Type: EXPERIMENTAL): Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks
- A, Stage 2 (Type: EXPERIMENTAL): Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks
- B, Stage 1 (Type: EXPERIMENTAL): Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks
- B, Stage 2 (Type: EXPERIMENTAL): Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).